Last reviewed · How we verify

NCT05098249

Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia

Completed Phase 4 Last updated 24 May 2023
What this trial tests

Phase 4 trial testing Verum in Anemia in 92 participants. Completed in 23 May 2023.

Timeline
11 November 2021
Primary endpoint
9 May 2023
23 May 2023

Quick facts

Lead sponsorDonat R. Spahn
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment92
Start date11 November 2021
Primary completion9 May 2023
Estimated completion23 May 2023
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

Donat R. Spahn — full company profile →

Who can join

18 and older, any sex, with Anemia or Iron-deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a confirmatory trial to establish superior serum phosphate stability associated with use of Phoscap® compared with placebo as a supplement for treatment of iron deficiency or iron deficiency anemia with Ferinject® before elective surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Verum

Trials testing the same drug.

Other recruiting trials for Anemia

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05098249.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing